Drug Trial Radar · NCT00992745
A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Oct 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 2009
Primary completion
Sep 2011
Study completion Sep 2011
Sponsor
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label study comparing the imaging characteristics of 123-I-MIP-1072 and ProstaScint® (111-In-capromab pendetide)in patients with metastatic prostate cancer. Eligible patients will receive a dose of 123-I-MIP-1072 and have imaging studies and safety assessments (physical examination, vital signs, electrocardiogram, clinical laboratory tests) performed during the subsequent 24 hours. Two weeks later, patients will return for additional safety assessments and will receive ProstaScint® if they don't already have a pre-existing ProstaScint scan. Final assessments will be performed two weeks after the ProstaScint® scan unless there is a difference between the 123-I-MIP-1072 and ProstaScint® scans. If this is the case, another dose of 123-I-MIP-1072 will be given 12 weeks later, and imaging studies repeated.
Conditions
- Prostate Cancer
Interventions
123-I-MIP-1072Drug
Single 10 mCi intravenous injection
111-In capromab pendetideDrug
Single 5 mCi intravenous injection
123-I-MIP-1072Drug
Single 5 mCi intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate the imaging sensitivity and specificity of 10.0 mCi or 5.0 mCi of 123I MIP 1072 compared to 5 mCi of 111In capromab pendetide in subjects with metastatic prostate cancer by determining the presence and extent of the disease.Time frame: 24 hours post-injection
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
West Coast Radiology Centers
Laguna Niguel, California
Pacific Coast Imaging
Newport Beach, California
University of California - San Francisco
San Francisco, California
University of Maryland
Baltimore, Maryland
New York Presbyterian Hospital - Weill Cornell Medical College
New York, New York
Duke University Medical Center
Durham, North Carolina
Vanguard Urologic Research Foundation
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.